
small organic compounds have been discovered, some of which have been successfully demonstrated to prevent or treat some chemokine-mediated diseases (reviewed in Rossi, et al., *ibid.*). Notably, in an experimental model of rheumatoid arthritis, disease development is diminished when a signaling-blocking, modified-RANTES ligand is administered (see Plater-Zyberk, et al., *Immunol Lett.* **57(1-3):**117-120 (1997)). While function-blocking antibody and small peptide therapies are promising, they suffer from the perils of degradation, extremely short half-lives once administered, and prohibitive expense to develop and manufacture, characteristic of most proteins. Small organic compounds are preferable since they often have longer half lives *in vivo*, require fewer doses to be effective, can often be administered orally, and are consequently less expensive. Some organic antagonists of CCR1 have been previously described (see, Hesselgesser, et al., *J. Biol. Chem.* **273(25):**15687-15692 (1998); Ng, et al., *J. Med. Chem.* **42(22):**4680-4694 (1999); Liang, et al., *J. Biol. Chem.* **275(25):**19000-19008 (2000); and Liang, et al., *Eur. J. Pharmacol.* **389(1):**41-49 (2000)). In view of the effectiveness demonstrated for treatment of disease in animal models (see, Liang, et al., *J. Biol. Chem.* **275(25):**19000-19008 (2000)), the search has continued to identify additional compounds that can be used in the treatment of diseases mediated by CCR1 signaling.

BRIEF SUMMARY

[0008] The present disclosure~~, in one aspect,~~ relates to compounds having formula I:



I

or any salts, hydrates, solvates, N-oxides or rotamers thereof; ~~W~~wherein n is an integer of from 0 to 3;

each A is independently selected from the group consisting of N and CH;

X and Z are each independently selected from the group consisting

(i) monocyclic or fused-bicyclic aryl and heteroaryl, wherein the heteroaryl group has from 1-4 heteroatoms as ring members selected from N, O and S;

(ii) monocyclic four-, five-, six- or seven-membered ring selected from the group consisting of cycloalkane, and heterocycloalkane, wherein the heterocycloalkane rings have from 1-3 heteroatoms as ring members selected from N, O and S;

wherein each of the rings in (i) and (ii) are optionally substituted with from 1 to 5 substituents selected from halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-SO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of the substituents are optionally further substituted with 1-3 R^a; and optionally, two substituents on adjacent ring vertices are connected to form an additional 5- or 6-membered ring which is saturated, unsaturated or aromatic having ring vertices selected from C, O, N and S;


R^3 is a member selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocyclic wherein the heteroatoms present as ring vertices of the heteroaryl and heterocyclic rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocyclic portions of R^3 are optionally further substituted with 1-3 R^a;

R^4 is a member selected from the group consisting of H, $-OR^a$ and C_{1-8} alkyl optionally substituted with $-OR^a$;

R^9 is a member selected from the group consisting of H and C_{1-8} alkyl optionally substituted with $-OR^a$;

each R^a and R^b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C_{1-8} alkyl, C_{1-8} alkoxy,C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkylalkyl, amino, C_{1-8} alkylamino, di C_{1-8} alkylamino, carboxamide, carboxy C_{1-4} alkyl ester, carboxylic acid, and $-SO_2-$ C_{1-8} alkyl.

[0008a] In one aspect of the present disclosure, there is provided a compound represented by the structure:



wherein

n is an integer of from 0 to 3

~~condition, an immunoregulatory disorder, transplant rejection, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, stroke, restenosis, encephalomyelitis, rheumatoid arthritis, multiple sclerosis, osteoarthritis, multiple myeloma and osteoporosis~~.

each A is independently selected from the group consisting of N and CH

A^1 is N or $C(R^5)$;

A^2 is N or $C(R^7)$;

R^1 and R^2 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-SO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heterocycloalkane ring are selected from N, O and S, and wherein the alkyl, cycloalkyl, and hetereocycloalkane portions of R^1 and R^2 are optionally further substituted with 1-3 R^a

R^3 is a member selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^3 are optionally further substituted with 1-3 R^a;

R^4 is a member selected from the group consisting of H, $-OR^a$ and C_{1-8} alkyl optionally substituted with $-OR^a$;

R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^5, R^6, R^7 and R^8 are are optionally further substituted with 1-3 R^a; and optionally, adjacent members of R^5, R^6, R^7 and R^8 are connected to form an additional 5- or 6-membered ring which is saturated, unsaturated or aromatic having ring vertices selected from C, O, N and S;

R^9 is a member selected from the group consisting of H and C_{1-8} alkyl optionally substituted with $-OR^a$


each R^a and R^b is independently selected from the group consisting of hydrogen,

hydroxyl, halogen, cyano, C_{1-8} alkyl, C_{1-8} alkoxy,C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkylalkyl, amino, C_{1-8} alkylamino, di C_{1-8} alkylamino, carboxamide, carboxy C_{1-4} alkyl ester, carboxylic acid, and $-SO_2-$ C_{1-8} alkyl;or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

[0009] In addition to the compounds provided herein, the present disclosure further provides pharmaceutical compositions containing one or more of these compounds, as well as methods for the use of these compounds primarily to treat diseases associated with CCR1 signalling activity. In another aspect, there is provided a pharmaceutical composition comprising the compound as defined herein and a pharmaceutically acceptable excipient or carrier. In another aspect, there is provided a compound as defined herein for use in treating CCR1-mediated diseases or conditions. In another aspect, there is provided use of a compound as defined herein in the manufacture of a medicament for the treatment of a CCR1-mediated disease or condition selected from the group consisting of an inflammatory condition, an immunoregulatory disorder, transplant rejection, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, stroke, restenosis, encephalomyelitis, rheumatoid arthritis, multiple sclerosis, osteoarthritis, multiple myeloma and osteoporosis.

WHAT IS CLAIMED IS:

1. A compound represented by the structure (I):



(I)

wherein n is an integer of from 0 to 3;

each A is independently selected from the group consisting of N and CH;

X and Z are each independently selected from the group consisting

(i) monocyclic or fused bicyclic aryl and heteroaryl, wherein the heteroaryl group has from 1-4 heteroatoms as ring members selected from N, O and S;

(ii) monocyclic four-, five-, six- or seven-membered ring selected from the group consisting of cycloalkane, and heterocycloalkane, wherein the heterocycloalkane rings have from 1-3 heteroatoms as ring members selected from N, O and S;

wherein each of the rings in (i) and (ii) are optionally substituted with from 1 to 5 substituents selected from halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-SO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of the substituents are optionally further substituted with 1-3 R^a; and optionally, two substituents on adjacent ring vertices are connected to form an additional 5- or 6-membered ring which is saturated, unsaturated or aromatic having ring vertices selected from C, O, N and S;

R^3 is a member selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^3 are optionally further substituted with 1-3 R^a;


R^4 is a member selected from the group consisting of H, $-OR^a$ and C_{1-8} alkyl optionally substituted with $-OR^a$;

R^9 is a member selected from the group consisting of H and C_{1-8} alkyl optionally substituted with $-OR^a$;

each R^a and R^b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkylalkyl, amino, C_{1-8} alkylamino, di C_{1-8} alkylamino, carboxamide, carboxy C_{1-4} alkyl ester, carboxylic acid, and $-SO_2-C_{1-8}$ alkyl,

or any salts, solvates, hydrates, N-oxides or rotamers thereof.

2. A compound of claim 1, represented by the structure:



wherein

A^1 is N or $C(R^5)$;

A^2 is N or $C(R^7)$;


R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, OR^a, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^5, R^6, R^7 and R^8 are are optionally further substituted with 1-3 R^a; and optionally, adjacent members of R^5, R^6, R^7 and R^8 are connected to form an additional 5- or 6-membered ring which is saturated, unsaturated or aromatic having ring vertices selected from C, O, N and S;

or a pharmaceutically acceptable salt, hydrate, solvate, rotamer or N-oxide thereof.

3. A compound of claim 2, wherein R^8 is other than H.

WHAT IS CLAIMED IS:

41. A compound of claim 2, represented by the structure:



wherein

n is an integer of from 0 to 3

each A is independently selected from the group consisting of N and CH

A^1 is N or $C(R^5)$;

A^2 is N or $C(R^7)$;

R^1 and R^2 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-SO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heterocycloalkane ring are selected from N, O and S, and wherein the alkyl, cycloalkyl, and hetereocycloalkane portions of R^1 and R^2 are optionally further substituted with 1-3 R^a

R^3 is a member selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^3 are optionally further substituted with 1-3 R^a;

R^4 is a member selected from the group consisting of H, $-OR^a$ and C_{1-8} alkyl optionally substituted with $-OR^a$;

R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, aryl, 5- or 6-membered heteroaryl, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heteroaryl and heterocycloalkane rings are selected from N, O and S, and wherein the alkyl, cycloalkyl, aryl, heteroaryl and hetereocycloalkane portions of R^5, R^6, R^7 and R^8 are are optionally further substituted with 1-3 R^a; and optionally, adjacent members of R^5, R^6, R^7 and R^8 are connected to form an additional 5- or 6-membered ring which is saturated, unsaturated or aromatic having ring vertices selected from C, O, N and S;

R^9 is a member selected from the group consisting of H and C_{1-8} alkyl optionally substituted with $-OR^a$


each R^a and R^b is independently selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkylalkyl, amino, C_{1-8} alkylamino, di C_{1-8} alkylamino, carboxamide, carboxy C_{1-4} alkyl ester, carboxylic acid, and $-SO_2-$ C_{1-8} alkyl;

or a pharmaceutically acceptable salt, hydrate, solvate, or rotamer thereof.

52. A compound of claim 41, wherein each R^1 and R^2 is independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{1-8} haloalkyl, $-CO_2R^a$ and $-SO_2R^a$.

63. A compound of claim 41, wherein R^9 is H or CH_3.


74. A compound of claim 41, represented by the structure:



wherein n is 1, 2 or 3


85. A compound of claim 74, wherein n is 1.

96. A compound of claim 41, wherein the ring portion having N, A^1 and A^2 as ring vertices is selected from the group consisting of:



wherein the wavy line indicates the point of attachment to the remainder of the compound.

107. A compound of claim 41, wherein the ring portion having N, A^1 and A^2 as ring vertices is selected from the group consisting of:




wherein

R^1 and R^2 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} haloalkyl, C_{1-8} hydroxyalkyl, $-OR^a$, $-CO_2R^a$, $-SO_2R^a$, $-NR^aR^b$, $-CONR^aR^b$, and 3-, 4-, 5- or 6-membered heterocycloalkane wherein the heteroatoms present as ring vertices of the heterocycloalkane ring are selected from N, O and S, and wherein the alkyl, cycloalkyl, and hetereocycloalkane portions of R^1 and R^2 are optionally further substituted with 1-3 R^a; and

R^7 is H or Cl, and R^8 is C_{1-8} alkyl optionally substituted with 1 or 2 R^a; and


wherein the wavy line indicates the point of attachment to the remainder of the compound.

~~118~~. A compound of claim ~~85~~, represented by the structure:




wherein R^1 is Cl or F.


~~129~~. A compound of claim ~~118~~, represented by the structure:




~~1310~~. A compound of claim ~~118~~, represented by the structure:



~~14~~11. A compound of claim ~~11~~8, represented by the structure:




~~15~~12. A compound of claim ~~8~~5, represented by the structure:




wherein R^1 is Cl or F.


~~16~~13. A compound of of claim ~~8~~5, represented by the structure:



~~17~~14. A compound of of claim ~~8~~5, represented by the structure:



~~18~~15. A compound of of claim ~~8~~5, represented by the structure:




~~19~~16. A compound of any of claims ~~10, 11, 12, 13, 16, 17 or 18~~7, 8, 9, 10, 13, 14 or 15, wherein R^3 is selected from the group consisting of H, $C_{1\text{-}8}$ alkyl, $C_{3\text{-}8}$ cycloalkyl and $C_{2\text{-}8}$ alkenyl.

17. A compound of claim 1, wherein

n is 1

the ring portion having N, A^1, and A^2 as ring vertices is selected from the group consisting of




R^1 and R^2 are each independently selected from the group consisting of H, halogen, CN, C_{1-8} alkyl, C_{1-8} haloalkyl, $-CO_2R^a$, and $-SO_2R^a$,

























R^3 is selected from the group consisting of H, C_{1-8} alkyl, C_{3-8} cycloalkyl and C_{2-8} alkenyl

R^7 is H or Cl, and R^8 is C_{1-8} alkyl optionally substituted with 1 or 2 R^a; and

R^9 is H or CH_3.

18. A compound of claim 1, selected from the group consisting of













,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,



,


,

,

,

,

,

,

,

, and


or a pharmaceutically acceptable salt, hydrate, or solvate thereof.





19. A compound of claim **1**, selected from the group consisting of


,

,

,

,

,

,

,

,

,

,

,



, 
and


or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

20. A compound of claim **1**, selected from the group consisting of




and



or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

21. A compound of claim **1**, having the formula



or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

22. A compound of claim **1**, having the formula



or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

~~20~~23. A pharmaceutical composition comprising the compound of any one of Claims **1, 17, 18, 19, 20 or 21** and a pharmaceutically acceptable excipient or carrier.

~~21. A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable excipient or carrier.~~

~~22~~24. A compound of Claims ~~2~~ 1, 18 or 20 for use in treating CCR1-mediated diseases or conditions.

~~23~~25. A compound in accordance with Claim ~~22~~24, wherein said CCR1-mediated disease or condition is an inflammatory condition.

~~24~~26. A compound in accordance with Claim ~~22~~24, wherein said CCR1-mediated disease or condition is an immunoregulatory disorder.

~~25~~27. A compound in accordance with Claim ~~22~~24, wherein said CCR1-mediated disease or condition is selected from the group consisting of transplant rejection, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, stroke, restenosis and encephalomyelitis

~~26~~28. A compound in accordance with Claim ~~22~~24, wherein said CCR1-mediated disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, osteoarthritis, multiple myeloma and osteoporosis.

~~27~~29. A compound in accordance with Claim ~~22~~24, wherein said compound is for oral, parenteral, rectal, transdermal, sublingual, nasal or topical administration.

~~28~~30. A compound in accordance with Claim ~~22~~24, wherein said compound is to be administered ~~for administration~~ in combination with an anti-inflammatory agent, analgesic agent, an anti-proliferative agent, a metabolic inhibitor, a leukocyte migration inhibitor or an immuno modulator.

~~29~~31. Use of a compound according to any one of Claims ~~2~~ 1, 17, 18, 19, 20 or 21 in the manufacture of a medicament for the treatment of a CCR1-mediated disease or condition selected from the group consisting of an inflammatory condition, an immunoregulatory disorder, transplant rejection, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, stroke, restenosis, encephalomyelitis, rheumatoid arthritis, multiple sclerosis, osteoarthritis, multiple myeloma and osteoporosis.